Form 4 for BIIB Biogen
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0001127602-23-005272 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-14 | 2023-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | +3,290 | 12.8K | +35% | $0 |
| DM | 2023-02-14 | 2023-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | F - Tax | $286.30 | -3,306 | 12.3K | -21% | -$946.5K |
| D | 2023-02-14 | 2023-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | J - Other | $0.00 | -1,384 | 0 | -100% | $0 |
| DM | 2023-02-14 | 2023-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | -3,290 | 1,384 | -70% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | M | A | 2,158 | $0.00 | 12,321.02 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-10 | F | D | 648 | $286.30 | 11,673.02 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-10 | F | D | 2,110 | $286.30 | 10,147.02 | D | — | — | (F1) Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. |
| 4 | Common | Common Stock | 2023-02-10 | F | D | 548 | $286.30 | 12,257.02 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-10 | M | A | 1,132 | $0.00 | 12,805.02 | D | — | — | |
| 6 | Derivative | Restricted Stock Unit | 2023-02-10 | J | D | 1,384 | $0.00 | 0 | D | $0.00 · — to 2023-02-12 | 1,384 Common Stock | (F4) This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. (F3) This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| 7 | Derivative | Restricted Stock Unit | 2023-02-10 | M | D | 2,158 | $0.00 | 4,317 | D | $0.00 · — to 2025-02-10 | 2,158 Common Stock | (F2) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. |
| 8 | Derivative | Restricted Stock Unit | 2023-02-10 | M | D | 1,132 | $0.00 | 1,384 | D | $0.00 · — to 2023-02-12 | 1,132 Common Stock | (F3) This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |